A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
University of Bristol has been crowned ‘AI University of The Year ... areas such as healthcare and robotics are expected to benefit hugely, and automated drug discovery and climate research should be ...
Sept. 13 (UPI) --The U.S. Food and Drug Administration has authorized software that can transform the latest version of Apple's AirPods Pro earbuds into hearing aids. The Thursday announcement ...
The Food and Drug Administration (BPOM) shoulders this critical responsibility, as outlined in Presidential Regulation No. 80/2017. The BPOM’s mandate extends beyond protecting domestic ...